20 results about "Sublingual administration" patented technology

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

A biphasic nutraceutical system designed to deliver GRAS-certified bioactive compound families across two circadian-aligned phases: a daytime formulation supporting metabolic activation and cognitive readiness, and a nighttime formulation facilitating nutritional regeneration and immune balance. Active compounds are encapsulated respectively within phospholipid-stabilized micellar vesicles for sublingual delivery and pH-sensitive polysaccharide hydrogel matrices for delayed absorption. This dual-phase structure enables non-invasive, phase-specific release and enhances nutrient bioavailability without invoking pharmacological mechanisms. The system integrates principles of nutritional chronobiology and adaptive timing to synchronize absorption with physiological receptivity windows. Exclusively composed of GRAS-aligned functional ingredients, it supports general biological function under non-clinical conditions, remaining fully within the regulatory scope of dietary supplements under 21 CFR § 170.30.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to sublingual lozenges of progesterone and analogues thereof as well as a preparation method and application of the sublingual lozenges. Specifically, a novel sublingual administration dosage form which is more suitable for being absorbed by a human body is designed according to physicochemical properties of progesterone and analogues thereof. The sublingual lozenge is composed of a main drug, a filler, a disintegrating agent, a mucous membrane promoter, a flavoring agent, a lubricant and the like. The sublingual lozenge is quickly disintegrated under the action of saliva, is quickly absorbed through tongue mucosa, takes effect quickly, avoids the first-pass effect, improves the bioavailability, and is suitable for various clinical scenes needing quick and efficient progestational hormone support.

The present disclosure relates to a pharmaceutical formulation suitable for sublingual administration for use in the treatment of obesity, type II diabetes, or related diseases. The pharmaceutical formula comprises 5 to 10 milligrams of glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) which is dissolved in 1.5 to 2.0 milliliters of a buffer solution, and the pH (Potential of Hydrogen) value of the pharmaceutical formula is 5.5 to 7.5. The disclosure also discloses a method for treating obesity, type II diabetes, or related diseases. The method comprises administering the pharmaceutical formulation of the present disclosure to a subject in a sublingual administration, and allowing the pharmaceutical formulation to be continuously located sublingually of the subject for 5-10 minutes, where the pharmaceutical formulation has a bioavailability for GLP-1 RA-P of 2-10% compared to the administration to the subject through subcutaneous injection.

Pharmaceutical compositions are described that include amorphous N-N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof and a polymeric carrier. These compositions are suitable for buccal or sublingual administration to patients. Methods for treating disorders, including neurological disorders, by administering these compositions are described.

To provide a composition or the like for treating agitation or signs of agitation.SOLUTION: The present invention discloses a method of treating agitation or signs of agitation in a subject comprising sublingual administration of an effective amount of an alpha-2 adrenergic agent, more particularly dexmedetomidine or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative diseases and / or neuropsychiatric diseases. The present invention also discloses sublingual administration of an alpha-2 adrenergic agent, more specifically dexmedetomidine or a pharmaceutically acceptable salt thereof, at a dose that is effective to treat agitation or the symptoms of agitation but does not cause significant sedation in the subject.SELECTED DRAWING: Figure 1A

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

The invention discloses an edaravone film quick-release preparation composition which comprises edaravone or pharmaceutically acceptable salts, prodrugs, metabolites, solvates, crystals or deuterated substances of edaravone and auxiliary materials. The weight percentage of the edaravone or the pharmaceutically acceptable salt, prodrug, metabolite, solvate, crystal or deuterated substance is 1%-60%. The edaravone oral cavity soluble film quick release preparation is used for sublingual administration, and has the characteristics of quick disintegration and good taste.

A biphasic nutraceutical system designed to deliver GRAS-certified bioactive compound families across two circadian-aligned phases: a daytime formulation supporting metabolic activation and cognitive readiness, and a nighttime formulation facilitating nutritional regeneration and immune balance. Active compounds are encapsulated respectively within phospholipid-stabilized micellar vesicles for sublingual delivery and pH-sensitive polysaccharide hydrogel matrices for delayed absorption. This dual-phase structure enables non-invasive, phase-specific release and enhances nutrient bioavailability without invoking pharmacological mechanisms. The system integrates principles of nutritional chronobiology and adaptive timing to synchronize absorption with physiological receptivity windows. Exclusively composed of GRAS-aligned functional ingredients, it supports general biological function under non-clinical conditions, remaining fully within the regulatory scope of dietary supplements under 21 CFR §170.30.

This is to provide a vaccine composition suitable for sublingual administration, a method of producing vaccine and a method of administering vaccine.This is to provide a vaccine composition for sublingual administration in a subject comprising an immune antigen and an adjuvant.

The application discloses a kind of enlicarabine sublingual preparations and preparation method thereof, the enlicarabine sublingual preparation includes the following component raw materials preparation: enlicarabine 2.5~50 parts, dissolving agent 5~20 parts, penetration agent 0.5~25 parts, excipient 17.5~405 parts;Wherein, the dissolving agent is sodium taurocholate, and the penetration agent is 8-(2-hydroxybenzamide) sodium octanoate.This enlicarabine sublingual preparation can be directly absorbed by sublingual mucosa under tongue, and after administration, drug absorption and effect are fast, and it is not necessary to take water, and effectively avoid the first pass effect of oral enlicarabine, wherein when cooperating with dissolving agent sodium taurocholate and penetration agent 8-(2-hydroxybenzamide) sodium octanoate, the solubility of enlicarabine can be obviously increased, and the mucosa absorption effect of enlicarabine can be obviously improved, the bioavailability and curative effect can be greatly improved, and it has good clinical use value and social benefits.

The present application relates to a new use of rutin or its hydrate, salt or derivative and injection thereof, and belongs to the field of biological medicine. The present application provides a use of rutin or its hydrate, salt or derivative in the preparation of a medicine for preventing or / and treating alcoholism; the medicine is an injection administration preparation, an oral administration preparation or a nasal administration preparation. The present application also provides a rutin injection prepared by including rutin in sulfobutyl-beta-cyclodextrin. The present application also provides a use of rutin or its hydrate, salt in the preparation of a dietary supplement for preventing hangover symptoms or abnormal behavior after drinking alcoholic beverages. The rutin injection or sublingual administration of the present application is safe and effective for treating alcoholism, and in addition, in the process of researching the rutin preparation, it is found that sulfobutyl-beta-cyclodextrin has a good solubilization effect on rutin, and when treating alcoholism, it can not only significantly shorten the sobering-up time, but also significantly reduce the mortality rate.

Described herein are formulations of a peptide derived from Chaperonin 60.1 suitable for sublingual administration. A dissolvable tablet pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This dissolvable tablet formulation includes a matrix-forming agent, a surfactant, a pH modifier, and a solvent. It may also contain sweeteners, flavor enhancers, or flavoring agents. In addition, a liquid pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This liquid pharmaceutical formulation includes the peptide, bovine serum albumin, and phosphate-buffered saline. The sublingual formulations achieve rapid systemic delivery comparable to IV administration. These formulations are intended for treating inflammatory conditions through sublingual administration. The formulations can be used for various inflammatory conditions and are adaptable for different administration frequencies and subject types.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

The invention discloses application of a cytisine-N-isoflavone derivative in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of biological medicine. The derivative is a compound CNI3, and the medicine takes the compound CNI3 or a pharmaceutically acceptable solvate thereof as an active ingredient; the dosage form can be selected from tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, gels, suppositories, ointments, emulsions and injections, and the administration route can be selected from oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration. Experiments in combination with in-vivo cell level and in-vitro animal level prove that the compound CNI3 promotes apoptosis of non-small cell lung cancer, exerts activity of resisting non-small cell lung cancer, has no obvious toxic or side effect on normal tissue cells, is good in safety, and has a good clinical application prospect when being used for preparing the medicine for resisting non-small cell lung cancer.

Provided are a vaccine composition suitable for sublingual administration, a vaccine production method and a vaccine administration method.　Provided is a vaccine composition that contains an immune antigen and an adjuvant and is to be sublingually administered to a subject.

This is to provide a vaccine composition suitable for sublingual administration, a method of producing vaccine and a method of administering vaccine. This is to provide a vaccine composition for sublingual administration in a subject comprising an immune antigen and an adjuvant.

The present invention relates to sublingual formulations having water-soluble co-crystals of acetylsalicylic acid with citric acid, sodium bicarbonate and L-theanine for the treatment of acute myocardial infarction. A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine eutectic composition is described, comprising an amount of acetylsalicylic acid. The composition may be produced by a process that includes different steps, including a co-crystallization step. The water soluble co-crystal composition is suitable for sublingual administration, preferably administration to a human.

Described herein are formulations of a peptide derived from Chaperonin 60.1 suitable for sublingual administration. A dissolvable tablet pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This dissolvable tablet formulation includes a matrix-forming agent, a surfactant, a pH modifier, and a solvent. It may also contain sweeteners, flavor enhancers, or flavoring agents. In addition, a liquid pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This liquid pharmaceutical formulation includes the peptide, bovine serum albumin, and phosphate-buffered saline. The sublingual formulations achieve rapid systemic delivery comparable to IV administration. These formulations are intended for treating inflammatory conditions through sublingual administration. The formulations can be used for various inflammatory conditions and are adaptable for different administration frequencies and subject types.

Disclosed in the present application is an edaravone film immediate-release formulation composition, comprising edaravone or a pharmaceutically acceptable salt, a prodrug, a metabolite, a solvate, a crystal, or a deuterated compound thereof, and an auxiliary material. Based on the weight of the composition, the weight percentage of the edaravone or the pharmaceutically acceptable salt, the prodrug, the metabolite, the solvate, the crystal, or the deuterated compound thereof is 1%-60%. The edaravone oral dissolving film immediate-release formulation of the present application is used for sublingual administration, and is characterized by fast disintegration and good mouthfeel.